Related references
Note: Only part of the references are listed.Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Validation of Bmi1 as a Therapeutic Target of Hepatocellular Carcinoma in Mice
Shibo Qi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2014)
Co-delivery of Doxorubicin and Bmi 1 siRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in vitro and in vivo
Tan Yang et al.
THERANOSTICS (2014)
Bmi1 Is Required for Hepatic Progenitor Cell Expansion and Liver Tumor Development
Lingling Fan et al.
PLOS ONE (2012)
Enhancing Chemotherapy Response with Bmi-1 Silencing in Ovarian Cancer
Enfeng Wang et al.
PLOS ONE (2011)
Overexpression of BMI-1 Promotes Cell Growth and Resistance to Cisplatin Treatment in Osteosarcoma
Zhihong Wu et al.
PLOS ONE (2011)
Expression of Bmi-1 is a prognostic marker in bladder cancer
Zi-Ke Qin et al.
BMC CANCER (2009)
Bmi1 Functions as an Oncogene Independent of Ink4A/Arf Repression in Hepatic Carcinogenesis
Chuan-Rui Xu et al.
MOLECULAR CANCER RESEARCH (2009)
Polycomb Group Protein Bmi1 Is Required for Growth of RAF Driven Non-Small-Cell Lung Cancer
Matthias Becker et al.
PLOS ONE (2009)
Bmi1 promotes prostate tumorigenesis via inhibiting p16INK4A and p14ARF expression
Catherine Fan et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2008)
BMI-1 promotes Ewing sarcoma tumorigenicity independent of CDKN2A repression
Dorothea Douglas et al.
CANCER RESEARCH (2008)
Molecular markers in bladder cancer
Shahrokh F. Shariat et al.
CURRENT OPINION IN UROLOGY (2008)
Bmi1 is critical for lung tumorigenesis and bronchioalveolar stem cell expansion
Jennifer Shepard Dovey et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer
Alexandra M. Pietersen et al.
BREAST CANCER RESEARCH (2008)
Distinct pathways of genomic progression to benign and malignant tumors of the liver
Aaron D. Tward et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Contribution of polycomb homologues Bmi-1 and Mel-18 to medulloblastoma pathogenesis
Dmitri Wiederschain et al.
MOLECULAR AND CELLULAR BIOLOGY (2007)
The polycomb group BMI1 gene is a molecular marker for predicting prognosis of chronic myeloid leukemia
Mohamad Mohty et al.
BLOOD (2007)
Bmi-1 is a novel molecular marker of nasopharyngeal carcinoma progression and immortalizes primary human nasopharyngeal epithelial cells
Li-Bing Song et al.
CANCER RESEARCH (2006)
Bmi1, stem cells, and senescence regulation
IK Park et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation
AV Molofsky et al.
NATURE (2003)
Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers
S Eissa et al.
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY (2003)
Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells
IK Park et al.
NATURE (2003)
Intravesical gemcitabine therapy for superficial transitional cell carcinoma of the bladder: A phase I and pharmacokinetic study
M Laufer et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)